ZA963959B - Tetralin compounds with improved mdr activity - Google Patents

Tetralin compounds with improved mdr activity

Info

Publication number
ZA963959B
ZA963959B ZA963959A ZA963959A ZA963959B ZA 963959 B ZA963959 B ZA 963959B ZA 963959 A ZA963959 A ZA 963959A ZA 963959 A ZA963959 A ZA 963959A ZA 963959 B ZA963959 B ZA 963959B
Authority
ZA
South Africa
Prior art keywords
compounds
mdr activity
tetralin compounds
improved
pharmaceutical compositions
Prior art date
Application number
ZA963959A
Other languages
English (en)
Inventor
Robert E Zelle
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ZA963959B publication Critical patent/ZA963959B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA963959A 1995-05-19 1996-05-17 Tetralin compounds with improved mdr activity ZA963959B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/444,567 US5726184A (en) 1995-05-19 1995-05-19 Tetralin compounds with improved MDR activity

Publications (1)

Publication Number Publication Date
ZA963959B true ZA963959B (en) 1996-11-25

Family

ID=23765456

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA963959A ZA963959B (en) 1995-05-19 1996-05-17 Tetralin compounds with improved mdr activity

Country Status (22)

Country Link
US (1) US5726184A (cs)
EP (1) EP0839143B1 (cs)
JP (1) JPH11505255A (cs)
KR (1) KR19990014848A (cs)
CN (1) CN1184475A (cs)
AT (1) ATE221881T1 (cs)
AU (1) AU705167B2 (cs)
BR (1) BR9608789A (cs)
CA (1) CA2219752A1 (cs)
CZ (1) CZ364197A3 (cs)
DE (1) DE69622871T2 (cs)
DK (1) DK0839143T3 (cs)
ES (1) ES2179945T3 (cs)
HU (1) HUP9802679A3 (cs)
IL (1) IL118269A0 (cs)
NO (1) NO975198L (cs)
NZ (1) NZ308789A (cs)
PL (1) PL323490A1 (cs)
PT (1) PT839143E (cs)
SK (1) SK155497A3 (cs)
WO (1) WO1996036630A1 (cs)
ZA (1) ZA963959B (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5935989A (en) 1996-12-31 1999-08-10 Gpi Nil Holdings Inc. N-linked ureas and carbamates of heterocyclic thioesters
EA002401B1 (ru) * 1996-12-31 2002-04-25 Джи Пи Ай Нил Холдингс, Инк. N-связанные мочевины и карбаматы сложных гетероциклических тиоэфиров
US5846979A (en) 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
FR2781218B1 (fr) 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6323215B1 (en) 1999-07-09 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
FR2797444B1 (fr) * 1999-08-13 2003-02-07 Lafon Labor Compositions pharmaceutiques comprenant des 4-quinolones
HUP0303719A2 (hu) * 2000-10-16 2004-03-01 Neopharm, Inc. Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra
US6376514B1 (en) * 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
CA2449019A1 (en) * 2001-05-29 2002-12-05 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
US20030109448A1 (en) * 2001-11-07 2003-06-12 Crowley Kathleen S. Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
WO2005007162A1 (en) * 2003-07-10 2005-01-27 Vertex Pharmaceuticals Incorporated Compounds augmenting the activity of antibacterial agents
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
WO2011031926A1 (en) 2009-09-11 2011-03-17 Vertex Pharmaceuticals Incorporated Compositions of n-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl) acetyl]amino]-n-[3-(4-pyridyl)-1-[2-[4-pyridyl)ethyl]propanamide and uses thereof
CN103130631A (zh) * 2011-11-29 2013-06-05 中国人民解放军第二军医大学 1-取代苯亚甲基-2-萘酮类衍生物及制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
US5387685A (en) * 1993-07-16 1995-02-07 American Cyanamid Co MDR reversal agents

Also Published As

Publication number Publication date
IL118269A0 (en) 1996-09-12
HUP9802679A2 (hu) 1999-03-29
PL323490A1 (en) 1998-03-30
WO1996036630A1 (en) 1996-11-21
KR19990014848A (ko) 1999-02-25
DE69622871T2 (de) 2003-04-10
CZ364197A3 (cs) 1998-03-18
ATE221881T1 (de) 2002-08-15
CN1184475A (zh) 1998-06-10
MX9708830A (es) 1998-03-31
AU5862096A (en) 1996-11-29
AU705167B2 (en) 1999-05-20
BR9608789A (pt) 1999-02-17
DK0839143T3 (da) 2002-11-18
HUP9802679A3 (en) 2000-03-28
CA2219752A1 (en) 1996-11-21
NO975198D0 (no) 1997-11-12
DE69622871D1 (de) 2002-09-12
US5726184A (en) 1998-03-10
EP0839143A1 (en) 1998-05-06
ES2179945T3 (es) 2003-02-01
PT839143E (pt) 2002-12-31
NZ308789A (en) 1999-07-29
JPH11505255A (ja) 1999-05-18
SK155497A3 (en) 1998-04-08
EP0839143B1 (en) 2002-08-07
NO975198L (no) 1998-01-19

Similar Documents

Publication Publication Date Title
ZA963959B (en) Tetralin compounds with improved mdr activity
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
EP1420009A3 (en) Novel amino acid derivatives with improved multi-drug resistance activity
ATE251140T1 (de) N-(2 oxoacetyl oder sulphonyl)- pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
IL107109A0 (en) Compounds for modifying drug resistance and pharmaceutical compositions containing the same
CA2186380A1 (en) Novel carbamates and ureas as modifiers of multi-drug resistance
FI953748A (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
IL118218A (en) Pharmaceutical compositions containing sarcodictyins
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
HUP9802536A3 (en) Pharmaceutical compositions containing 1,2,4-benzotriazine 1,4-dioxide and use thereof for the preparation of pharmaceutical compositions treating cancer
TR199901385T2 (xx) Piperidin t�revleri.
TR199800705T2 (cs)
TR200000916T2 (tr) İkameli piperidin türevleri.